Clinical Trial Update: Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating dosing of sorafenib in patients with pulmonary arterial hypertension has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: University of Chicago | Conditions: Pulmonary Arterial Hypertension | Phase 1 | Status: COMPLETED